Vaccines And Advair Keep GSK’s Earnings Steady Despite Avandia Losses

Despite losses from generic competition and falling Avandia sales, strong performances from GlaxoSmithKline's vaccines business and asthma therapy Advair kept its third quarter earnings fairly consistent with the year-ago period